Buy Stalevo (Levodopa with Carbidopa and Entacapone) online

Buy Stalevo (Levodopa with Carbidopa and Entacapone) for Parkinson's disease
Cheap qualitative Carbidopa, Levodopa, Entacapone 25/100/200 mg tablets online



HOW AND WHERE TO BUY STALEVO (CARBIDOPA, LEVODOPA, ENTACAPONE) 25 MG / 100 MG / 200 MG TABLETS OR CAPSULES ONLINE:

STALEVO (LEVODOPA WITH CARBIDOPA AND ENTACAPONE) TABLETS: PRESCRIBING INFORMATION

DESCRIPTION

Stalevo (Carbidopa, Levodopa and Entacapone) is a combination of carbidopa, levodopa and entacapone for the treatment of Parkinson's disease.

Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (-)-L-(alpha-hydrazino-(alpha-methyl-beta-(3,4-dihydroxybenzene) propanoic acid monohydrate. Its empirical formula is C10H14N2O4xH2O.

Tablet content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.3.

Levodopa, an aromatic amino acid, is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (-)-L-alpha-amino-beta(3,4-dihydroxybenzene) propanoic acid. Its empirical formula is C9H11NO4.

Entacapone, an inhibitor of catechol-O-methyltransferase (COMT), is a nitro-catechol-structured compound with a molecular weight of 305.3. The chemical name of entacapone is (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide. Its empirical formula is C14H15N3O5.

Stalevo (Levodopa/Carbidopa/Entacapone) is supplied as tablets in six strengths: Stalevo 50, containing 12.5 mg of carbidopa, 50 mg of levodopa and 200 mg of entacapone; Stalevo 75, containing 18.75 mg of carbidopa, 75 mg of levodopa and 200 mg of entacapone; Stalevo 100, containing 25 mg of carbidopa, 100 mg of levodopa and 200 mg of entacapone; Stalevo 125, containing 31.25 mg of carbidopa, 125 mg of levodopa and 200 mg of entacapone; Stalevo 150, containing 37.5 mg of carbidopa, 150 mg of levodopa and 200 mg of entacapone; Stalevo 200, containing 50 mg of carbidopa, 200 mg of levodopa and 200 mg of entacapone.

The inactive ingredients of the Stalevo tablet are croscarmellose sodium, corn starch, glycerol 85%, magnesium stearate, hypromellose, mannitol, povidone, polysorbate 80, sucrose, red iron oxide, and titanium dioxide.

Stalevo 50, Stalevo 100, and Stalevo 150 also contain yellow iron oxide.


CLINICAL PHARMACOLOGY

Stalevo clinical pharmacology


PHARMACOKINETICS

Stalevo pharmacokinetics


PHARMACOKINETICS IN SPECIAL POPULATIONS

Stalevo pharmacokinetics in special populations


CLINICAL STUDIES

Stalevo clinical studies


INDICATIONS

Stalevo (Levodopa with Carbidopa and Entacapone) is indicated to treat patients with idiopathic Parkinson's disease:

1. To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products.

2. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias.


CONTRAINDICATIONS

Stalevo (Levodopa with Carbidopa and Entacapone) tablets are contraindicated in patients who have demonstrated hypersensitivity to any component (carbidopa, levodopa, or entacapone) of the drug or its excipients. Monoamine oxidase (MAO) and COMT are the two major enzyme systems involved in the metabolism of catecholamines. It is theoretically possible, therefore, that the combination of entacapone and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. As with carbidopa-levodopa, nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with Stalevo. These inhibitors must be discontinued at least two weeks prior to initiating therapy with Stalevo. Stalevo may be administered concomitantly with the manufacturer's recommended dose of MAO inhibitors with selectivity for MAO type B (e.g., selegiline HCl).

Stalevo is contraindicated in patients with narrow-angle glaucoma.

Because levodopa may activate malignant melanoma, Stalevo should not be used in patients with suspicious, undiagnosed skin lesions or a history of melanoma.


WARNINGS

Stalevo warnings


PRECAUTIONS

Stalevo precautions


SPECIAL PRECAUTIONS

Stalevo special precautions


LABORATORY TESTS

Stalevo laboratory tests


DRUG INTERACTIONS

Stalevo drug interactions


NONCLINICAL TOXICOLOGY

Stalevo nonclinical toxicology


USE IN SPECIAL POPULATIONS

Stalevo use in special populations


ADVERSE REACTIONS

Stalevo adverse reactions


DRUG ABUSE AND DEPENDENCE

Controlled substance class

Stalevo (Levodopa/Carbidopa/Entacapone) is not a controlled substance in the USA.

Physical and psychological dependence

Stalevo has not been systematically studied, in animal or humans, for its potential for abuse, tolerance or physical dependence. In premarketing clinical experience, carbidopa-levodopa did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior. However, there are rare postmarketing reports of abuse and dependence of medications containing levodopa. In general, these reports consist of patients taking increasing doses of medication in order to achieve a euphoric state.


DOSAGE AND ADMINISTRATION

Stalevo dosage and administration


OVERDOSAGE

Stalevo overdosage


HOW SUPPLIED

Stalevo how supplied

Manufactured and distributed by Novartis, Orion Corporation pharmaceutical companies and their divisions.

Recent posts:

  • Buy Stalevo (Carbidopa, Levodopa, Entacapone) Online

    Copyright © Buy Stalevo (Levodopa with Carbidopa and Entacapone) Online